Equities

Dermata Therapeutics Inc

DRMA:NAQ

Dermata Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.84
  • Today's Change0.215 / 5.94%
  • Shares traded43.75k
  • 1 Year change-84.02%
  • Beta--
Data delayed at least 15 minutes, as of May 31 2024 20:59 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, DMT310, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 50 million patients. Its second product candidate utilizing its Spongilla technology is DMT410, its combination treatment. DMT410 is intended to consist of one treatment of its proprietary sponge powder followed by one topical application of botulinum toxin for delivery into the dermis.

  • Revenue in USD (TTM)0.00
  • Net income in USD-8.69m
  • Incorporated2014
  • Employees8.00
  • Location
    Dermata Therapeutics Inc3525 Del Mar Heights Rd., #322SAN DIEGO 92130United StatesUSA
  • Phone+1 (858) 223-0882
  • Fax+1 (302) 636-5454
  • Websitehttps://www.dermatarx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Virpax Pharmaceuticals Inc0.00-16.89m1.48m7.00---------14.42-14.420.00-1.040.00----0.00-156.21-87.52-241.52-116.56--------------------29.84------
180 Life Sciences Corp0.00-16.24m1.53m4.00---------41.54-41.540.00-1.120.00----0.00-176.90-42.39-354.57-56.41-----------385.88--------48.52------
Bluejay Diagnostics Inc0.00-9.74m1.54m10.00--0.4232-----7.68-7.680.001.250.00----0.00-122.06---149.68--------------0.0048---100.00---7.07------
Finch Therapeutics Group Inc0.00-16.28m1.55m18.00--0.0816-----10.14-10.140.0011.860.00-------25.22---28.97--------------0.00---87.57--34.80------
InVitro International716.89k6.22k1.57m16.00197.342.15--2.190.00040.00040.04020.03211.15------0.9957.891.098.83----0.86765.90---------5.111.33-87.77-16.14----
Target Group Inc5.64m228.87k1.57m46.0019.62--1.480.2790.00010.00010.0088-0.01150.7648.60124.27115,104.103.10-37.99---78.7643.71--4.06-586.970.07360.01493.10----577.8392.84---58.54--
Mallinckrodt PLC1.91bn-1.49bn1.60m2.80k------0.0008-161.65-161.6389.6355.440.40621.574.94681,821.40-31.61-12.49-36.10-15.8526.2235.68-77.83-44.381.63-0.34560.6164---2.53-10.31-83.00------
Procyon Corp4.77m-387.79k1.62m17.00--0.764--0.3397-0.0478-0.04780.58910.27741.391.949.60280,817.70-10.813.52-13.694.2378.0173.30-7.782.522.22--0.00---3.223.1170.44--30.98--
Stemcell Holdings Inc9.98m3.10m1.64m------0.50080.16450.000080.000080.00030.00021.12--5.20--34.90--68.19--77.19--31.04------0.00--85.10--71.82------
Dermata Therapeutics Inc0.00-8.69m1.70m8.00--6.71-----24.67-24.670.000.57170.00----0.00-120.05---146.08--------------0.00------18.90------
Qualigen Therapeutics Inc0.00-12.48m1.70m4.00---------2.46-2.640.00-0.39230.00----0.00-118.15---364.72--21.30---------7.41--------10.22------
PainReform Ltd0.00-12.54m1.76m6.00--0.7109-----7.77-7.770.000.99880.00----0.00-158.88-55.47-222.89-68.20------------0.00-------6.28------
Hi-Great Group Holding Co109.49k-121.76k1.78m--------16.26-0.0012-0.00120.0011-0.00110.82240.8406-----91.46------46.50---111.21--0.0144-52.41-----47.32---3,789.70------
SYBLEU Inc11.70k-307.88k1.84m--------157.17-0.0293-0.02930.0011-0.03670.0641-------168.63-----------2,631.45-----8.484.96--0.00--26.51------
SOHM Inc-100.00bn-100.00bn1.84m--------------------------------------------------------------
CanaQuest Medical Corp0.00-808.07k1.92m-----------0.0514-0.05140.00-0.0370.00-------1,084.38--------------------------57.42------
Data as of May 31 2024. Currency figures normalised to Dermata Therapeutics Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.